Literature DB >> 23331046

Model-based approaches to predict drug-drug interactions associated with hepatic uptake transporters: preclinical, clinical and beyond.

Hugh A Barton1, Yurong Lai, Theunis C Goosen, Hannah M Jones, Ayman F El-Kattan, James R Gosset, Jian Lin, Manthena V Varma.   

Abstract

INTRODUCTION: Membrane transporters have been recognized to play a key role in determining the absorption, distribution and elimination processes of drugs. The organic anion-transporting polypeptide (OATP)1B1 and OATP1B3 isoforms are selectively expressed in the human liver and are known to cause significant drug-drug interactions (DDIs), as observed with an increasing number of drugs. It is evident that DDIs involving hepatic transporters are capable of altering systemic, as well as tissue-specific, exposure of drug substrates resulting in marked differences in drug safety and/or efficacy. It is therefore essential to quantitatively predict such interactions early in the drug development to mitigate clinical risks. AREAS COVERED: The role of hepatic uptake transporters in drug disposition and clinical DDIs has been reviewed with an emphasis on the current state of the models applicable for quantitative predictions. The readers will also gain insight into the in vitro experimental tools available to characterize transport kinetics, while appreciating the knowledge gaps in the in vitro-in vivo extrapolation (IVIVE), which warrant further investigation. EXPERT OPINION: Static and dynamic models can be convincingly applied to quantitatively predict drug interactions, early in drug discovery, to mitigate clinical risks as well as to avoid unnecessary clinical studies. Compared to basic models, which focus on individual processes, mechanistic models provide the ability to assess DDI potential for compounds with systemic disposition determined by both transporters and metabolic enzymes. However, complexities in the experimental tools and an apparent disconnect in the IVIVE of transport kinetics have limited the physiologically based pharmacokinetic modeling strategies. Emerging data on the expression of transporter proteins and tissue drug concentrations are expected to help bridge these gaps. In addition, detailed characterization of substrate kinetics can facilitate building comprehensive mechanistic models.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23331046     DOI: 10.1517/17425255.2013.759210

Source DB:  PubMed          Journal:  Expert Opin Drug Metab Toxicol        ISSN: 1742-5255            Impact factor:   4.481


  15 in total

Review 1.  Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation Approaches: A Systematic Review of Published Models, Applications, and Model Verification.

Authors:  Jennifer E Sager; Jingjing Yu; Isabelle Ragueneau-Majlessi; Nina Isoherranen
Journal:  Drug Metab Dispos       Date:  2015-08-21       Impact factor: 3.922

2.  Predicting Clearance Mechanism in Drug Discovery: Extended Clearance Classification System (ECCS).

Authors:  Manthena V Varma; Stefanus J Steyn; Charlotte Allerton; Ayman F El-Kattan
Journal:  Pharm Res       Date:  2015-07-09       Impact factor: 4.200

Review 3.  How Transporters Have Changed Basic Pharmacokinetic Understanding.

Authors:  Leslie Z Benet; Christine M Bowman; Jasleen K Sodhi
Journal:  AAPS J       Date:  2019-09-03       Impact factor: 4.009

4.  Identification of Transporters Involved in Beraprost Sodium Transport In Vitro.

Authors:  Keiyu Oshida; Masahiro Shimamura; Kazuhiro Seya; Akihiro Ando; Yohei Miyamoto
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-02       Impact factor: 2.441

Review 5.  Prediction of pharmacokinetics and drug-drug interactions when hepatic transporters are involved.

Authors:  Rui Li; Hugh A Barton; Manthena V Varma
Journal:  Clin Pharmacokinet       Date:  2014-08       Impact factor: 6.447

6.  The Extended Clearance Concept Following Oral and Intravenous Dosing: Theory and Critical Analyses.

Authors:  Leslie Z Benet; Christine M Bowman; Shufang Liu; Jasleen K Sodhi
Journal:  Pharm Res       Date:  2018-10-22       Impact factor: 4.200

7.  Challenging the Relevance of Unbound Tissue-to-Blood Partition Coefficient (Kpuu) on Prediction of Drug-Drug Interactions.

Authors:  Jasleen K Sodhi; Shuaibing Liu; Leslie Z Benet
Journal:  Pharm Res       Date:  2020-03-25       Impact factor: 4.200

8.  Mechanism-based pharmacokinetic modeling to evaluate transporter-enzyme interplay in drug interactions and pharmacogenetics of glyburide.

Authors:  Manthena V S Varma; Renato J Scialis; Jian Lin; Yi-An Bi; Charles J Rotter; Theunis C Goosen; Xin Yang
Journal:  AAPS J       Date:  2014-05-17       Impact factor: 4.009

9.  Effect of Ondansetron on Metformin Pharmacokinetics and Response in Healthy Subjects.

Authors:  Qing Li; Hong Yang; Dong Guo; Taolan Zhang; James E Polli; Honghao Zhou; Yan Shu
Journal:  Drug Metab Dispos       Date:  2016-01-29       Impact factor: 3.922

10.  Role of OATP-1B1 and/or OATP-1B3 in hepatic disposition of tyrosine kinase inhibitors.

Authors:  Varun Khurana; Mukul Minocha; Dhananjay Pal; Ashim K Mitra
Journal:  Drug Metabol Drug Interact       Date:  2014
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.